Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer

[1]  S. Plymate,et al.  Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. , 2016, Cancer research.

[2]  E. Petricoin,et al.  Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis , 2015, PloS one.

[3]  S. Gambhir,et al.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.

[4]  Michael D. Nyquist,et al.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies , 2015, Nucleic acids research.

[5]  B. Dai,et al.  Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer , 2015, Scientific Reports.

[6]  K. Haugk,et al.  MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand , 2014, Oncotarget.

[7]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[8]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[9]  M. Garcia-Blanco,et al.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. , 2014, Endocrine-related cancer.

[10]  Jun Luo,et al.  Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone , 2014, Hormones and Cancer.

[11]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[12]  J. Luo,et al.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects , 2014, Oncogene.

[13]  Zhiyong Guo,et al.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.

[14]  H. Scher,et al.  First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer , 2013, British Journal of Cancer.

[15]  C. Evans,et al.  NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants , 2013, Molecular Cancer Therapeutics.

[16]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[17]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[18]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[19]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[20]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[21]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[22]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[23]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[24]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[25]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[27]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[28]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.